FDA

Company

Last mentioned: Mar 22, 2026

Timeline

  1. Clinical Guidance

    Expected release of preliminary federal protocols for detransition medical management.

  2. Regulatory Review

    Anticipated commencement of HHS review into federal funding for gender-affirming clinics.

  3. FDA Type B Meeting

    Planned follow-up meeting to define the Phase III pathway for AMT-130 in Huntington's disease.

  4. AMT-260 Data

    Clinical data expected from the Phase I/IIa study in refractory mesial temporal lobe epilepsy.

  5. Policy Announcement

    Assistant Secretary Brian Christine declares detransition care a top priority for HHS.

  6. Initial Inquiry

    The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.

  7. Investigation Announced

    Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.

  8. Commissioner Meeting

    Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.

  9. Q4 2025 Earnings

    Company reports 25% total revenue growth and progress in clinical diagnostic pivot.

  10. Earnings Release

    Company announces 2025 results and provides update on FDA Type A meeting.

  11. FDA U-Turn

    FDA agrees to review the application after resolving the public dispute.

  12. Political Controversy

    Reports emerge that the vaccine chief overruled career scientists to block the shot.

  13. FDA 510(k) Submission

    Premarket notification submitted for Lucent AD Complete diagnostic test.

  14. Refusal to File

    FDA issues a shocking rejection of the application, sparking a public dispute.

  15. The Regulatory Gap

    Widespread adoption of AI by patients and doctors occurs ahead of formal FDA approval or clinical guidelines.

  16. CMS Reimbursement Milestone

    CMS approves $897 reimbursement rate for Lucent AD Complete, establishing a national reference price.

  17. Fiscal Year End

    uniQure closes 2025 with $622.5M in cash and equivalents.

  18. Initial BLA Submission

    Moderna submits its Biologics License Application for mRNA-1010.

  19. Assay Portfolio Expansion

    Launch of 13 new assays including pTau-205 and pTau-212 for neurodegenerative research.

  20. The LLM Breakthrough

    Launch of ChatGPT and Claude triggers exponential growth in interactive, human-like AI accessibility.

Stories mentioning FDA 7

pharma Neutral

AI and the Physician: Navigating the Shift from Clinical Tools to LLMs

The rapid proliferation of large language models (LLMs) like ChatGPT and Claude is fundamentally altering the physician-patient dynamic, moving beyond traditional clinical decision support into unregulated, interactive medical consultation. Bioethicist Dr. John Lantos warns that while AI has assisted doctors for decades, the current democratization of these tools via smartphones creates a regulatory vacuum that challenges the traditional authority of medical professionals.

3 sources
pharma Neutral

HHS Signals Major Policy Shift: Detransition Care Named a Top Priority

HHS Assistant Secretary Brian Christine has announced that detransition care will become a primary focus for the department, marking a significant pivot in federal healthcare policy. This shift is expected to influence clinical guidelines, pharmaceutical regulation, and federal funding for gender-related medical interventions.

3 sources
pharma Neutral

GOP Senator Probes FDA Over Rare Disease Drug Rejections

Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.

2 sources
pharma Bearish

FDA Vaccine Chief Departs Amid Regulatory Turmoil and Political Pressure

The head of the FDA’s vaccine division is stepping down for the second time, marking a significant leadership vacuum at a critical juncture for the agency. This departure follows a period of intense scrutiny and reported friction between the regulatory body and the Trump administration over vaccine authorization protocols.

6 sources
pharma Bullish

Quanterix Advances Alzheimer’s Strategy Amidst 25% Revenue Growth and FDA Filing

Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.

6 sources

About FDA coverage

This page surfaces every story mentioning FDA across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.

What you seeWhat it tells you
Story countNumber of distinct stories where FDA was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.